These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 24395207)

  • 1. Adaptive designs with arbitrary dependence structure.
    Schmidt R; Faldum A; Witt O; Gerss J
    Biom J; 2014 Jan; 56(1):86-106. PubMed ID: 24395207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two-stage adaptive designs with correlated test statistics.
    Hommel G; Lindig V; Faldum A
    J Biopharm Stat; 2005; 15(4):613-23. PubMed ID: 16022167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adaptive designs with correlated test statistics.
    Götte H; Hommel G; Faldum A
    Stat Med; 2009 May; 28(10):1429-44. PubMed ID: 19226563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On efficient two-stage adaptive designs for clinical trials with sample size adjustment.
    Liu Q; Li G; Anderson KM; Lim P
    J Biopharm Stat; 2012; 22(4):617-40. PubMed ID: 22651105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Data-driven analysis strategies for proportion studies in adaptive group sequential test designs.
    Wassmer G
    J Biopharm Stat; 2003 Nov; 13(4):585-603. PubMed ID: 14584710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maximum type 1 error rate inflation in multiarmed clinical trials with adaptive interim sample size modifications.
    Graf AC; Bauer P; Glimm E; Koenig F
    Biom J; 2014 Jul; 56(4):614-30. PubMed ID: 24753160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An adaptive approach to implementing bivariate group sequential clinical trial designs.
    Todd S
    J Biopharm Stat; 2003 Nov; 13(4):605-19. PubMed ID: 14584711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of experiments with adaptive interim analyses.
    Bauer P; Köhne K
    Biometrics; 1994 Dec; 50(4):1029-41. PubMed ID: 7786985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trimmed weighted Simes' test for two one-sided hypotheses with arbitrarily correlated test statistics.
    Brannath W; Bretz F; Maurer W; Sarkar S
    Biom J; 2009 Dec; 51(6):885-98. PubMed ID: 20014203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing trial design in pharmacogenetics research: comparing a fixed parallel group, group sequential, and adaptive selection design on sample size requirements.
    Boessen R; van der Baan F; Groenwold R; Egberts A; Klungel O; Grobbee D; Knol M; Roes K
    Pharm Stat; 2013; 12(6):366-74. PubMed ID: 24214896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adaptive trial design: a general methodology for censored time to event data.
    Jahn-Eimermacher A; Ingel K
    Contemp Clin Trials; 2009 Mar; 30(2):171-7. PubMed ID: 19130902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interim analysis incorporating short- and long-term binary endpoints.
    Niewczas J; Kunz CU; König F
    Biom J; 2019 May; 61(3):665-687. PubMed ID: 30694566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimation in flexible two stage designs.
    Brannath W; König F; Bauer P
    Stat Med; 2006 Oct; 25(19):3366-81. PubMed ID: 16220489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Type I error rate control in adaptive designs for confirmatory clinical trials with treatment selection at interim.
    Posch M; Maurer W; Bretz F
    Pharm Stat; 2011; 10(2):96-104. PubMed ID: 22328314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adaptive design clinical trials and trial logistics models in CNS drug development.
    Wang SJ; Hung HM; O'Neill R
    Eur Neuropsychopharmacol; 2011 Feb; 21(2):159-66. PubMed ID: 20933373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The advantages and disadvantages of adaptive designs for clinical trials.
    Bauer P; Brannath W
    Drug Discov Today; 2004 Apr; 9(8):351-7. PubMed ID: 15081962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biostatistical methods for demonstrating efficacy in the regulatory setting. An epistemological approach to adaptive designs.
    Koch A
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 May; 48(5):572-9. PubMed ID: 15887068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimized multi-stage designs controlling the false discovery or the family-wise error rate.
    Zehetmayer S; Bauer P; Posch M
    Stat Med; 2008 Sep; 27(21):4145-60. PubMed ID: 18444249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimization of adaptive designs: efficiency evaluation.
    Menon S; Chang M
    J Biopharm Stat; 2012; 22(4):641-61. PubMed ID: 22651106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accurate p-values for adaptive designs with binary endpoints.
    Heritier S; Lloyd CJ; Lô SN
    Stat Med; 2017 Jul; 36(17):2643-2655. PubMed ID: 28470713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.